Overview

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Status:
Recruiting
Trial end date:
2028-03-10
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD(Bortezomib, Lenalidomide and Dexamethasone) regimen combined with BCMA CAR-T in Chinese transplant-ineligible patients with newly diagnosed multiple myeloma
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital